152.60
-0.20
(-0.13%)
At close: April 17 at 5:03:07 PM GMT+2
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 14 | 13 | 23 | 22 |
| Avg. Estimate | 12.91B | 14.75B | 59.49B | 64.29B |
| Low Estimate | 12.7B | 14.35B | 58.7B | 61.62B |
| High Estimate | 13.35B | 15.11B | 60.55B | 66.62B |
| Year Ago Sales | 12.31B | 14.46B | 56.33B | 59.49B |
| Sales Growth (year/est) | 4.87% | 2.01% | 5.60% | 8.07% |
EPS Trend
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | 0 | 0 | 0 | 0 |
| 30 Days Ago | 0 | 0 | 0 | 0 |
| 60 Days Ago | 0 | 0 | 0 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| 4AB.F | -- | -- | -- | -- |
| S&P 500 | 7.04% | 5.20% | 8.89% | 14.14% |
Upgrades & Downgrades
| Reiterates | Guggenheim: Buy to Buy | 4/17/2025 |
| Maintains | Morgan Stanley: Overweight to Overweight | 4/9/2025 |
| Maintains | Wells Fargo: Overweight to Overweight | 3/5/2025 |
| Maintains | B of A Securities: Neutral to Neutral | 3/4/2025 |
| Maintains | Citigroup: Buy to Buy | 2/3/2025 |
| Maintains | Truist Securities: Buy to Buy | 2/3/2025 |
Related Tickers
BRM.MU Bristol-Myers Squibb Co
43.73
-0.08%
NOTA.BE Novartis AG
97.40
+3.18%
MRK.MX Merck & Co., Inc.
1,560.00
-2.80%
NOV.MU Novo Nordisk A/S
51.72
-7.03%
PFE.CL Pfizer Inc.
95,280.00
-2.60%
SNW.HM Sanofi SA
90.38
+0.33%
NOTA.DU Novartis AG
97.40
+0.62%
BAYZF Bayer Aktiengesellschaft
23.65
0.00%
GLAXO.BO GlaxoSmithKline Pharmaceuticals Limited
2,909.25
-0.66%
NOVA.F Novo Nordisk A/S
51.00
-6.42%